Peritonitis

Medicines360 and DKT WomanCare Announce Strategic Partnership to Expand Access to the Hormonal IUD Avibela™

Retrieved on: 
Wednesday, January 31, 2024

"As a global nonprofit pharmaceutical organization dedicated to expanding access to affordable reproductive health products for women, DKT WomanCare is an ideal partner for our organization," said Dr. Andrea Olariu, CEO of Medicines360.

Key Points: 
  • "As a global nonprofit pharmaceutical organization dedicated to expanding access to affordable reproductive health products for women, DKT WomanCare is an ideal partner for our organization," said Dr. Andrea Olariu, CEO of Medicines360.
  • “DKT WomanCare looks forward to leveraging our global partnerships and commercial relationships to ensure every woman, regardless of income, can access affordable, high-quality contraception.
  • As the supplier of AVIBELA, Medicines360 will focus on providing quality assurance and regulatory oversight, as well as ensuring sustainable product supply to DKT WomanCare and global procurement agencies.
  • Together, Medicines360 and DKT WomanCare will meet the growing demand for quality-assured, affordable hormonal IUDs and help build a robust and sustainable global contraceptive market.

BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325/DB-1305

Retrieved on: 
Wednesday, January 31, 2024

BNT325/DB-1305 is a next-generation antibody-drug conjugate (“ADC”) candidate targeting the trophoblast cell-surface antigen 2 (“TROP2”), a protein which is overexpressed on a range of tumor types.

Key Points: 
  • BNT325/DB-1305 is a next-generation antibody-drug conjugate (“ADC”) candidate targeting the trophoblast cell-surface antigen 2 (“TROP2”), a protein which is overexpressed on a range of tumor types.
  • The candidate is currently being evaluated in an ongoing Phase 1/2 study ( NCT05438329 ) in patients with TROP2-expressing advanced solid tumors.
  • Platinum-based chemotherapy is the backbone of treatment for ovarian epithelial cancer and related subtypes that form in the epithelial tissue.
  • “Recent studies have indicated the role of TROP2 in aggressive tumor growth and progression in patients with chemotherapy-resistant ovarian tumors.

Fapon, LASCCO, Abionic Formed Strategic Collaboration for PSP Sepsis Diagnosis in China

Retrieved on: 
Thursday, October 26, 2023

This strategic partnership will usher in a significant breakthrough in the medical field, removing barriers to early sepsis diagnosis.

Key Points: 
  • This strategic partnership will usher in a significant breakthrough in the medical field, removing barriers to early sepsis diagnosis.
  • Performing PSP testing on high-risk individuals can flag potential sepsis before the onset of clinical symptoms.
  • However, these methods cannot meet the clinical needs for early diagnosis of sepsis as they have major limitations.
  • Obtaining the PSP license for the diagnosis of sepsis will further enhance Fapon's potential for innovative applications in the diagnosis of infectious diseases.

PharmaJet, Nigeria’s National Primary Health Care Development Agency, and Health-focused Consortium Begin Implementation of Study Using Tropis® ID for Routine Immunization

Retrieved on: 
Tuesday, October 24, 2023

Partners are also evaluating the acceptability and feasibility of using needle-free from the healthcare worker and caregiver perspective.

Key Points: 
  • Partners are also evaluating the acceptability and feasibility of using needle-free from the healthcare worker and caregiver perspective.
  • View the full release here: https://www.businesswire.com/news/home/20231024060890/en/
    Nigerian baby receiving polio vaccine with the PharmaJet Tropis® Precision Needle-free System.
  • Evidence from the study is intended to inform policy regarding intradermal delivery of polio vaccine in routine immunization settings.
  • Study preparation included the development of standard operating procedures to ensure congruence with the country’s existing medical guidelines.

Terns Pharmaceuticals Announces Leadership Transition

Retrieved on: 
Thursday, August 3, 2023

Mr. Sundaram also resigned from the Board of Directors of Terns but will remain on as a Senior Advisor to the Company.

Key Points: 
  • Mr. Sundaram also resigned from the Board of Directors of Terns but will remain on as a Senior Advisor to the Company.
  • Erin Quirk, M.D., President and Head of Research & Development at Terns, will assume leadership of the Company, effective immediately.
  • “On behalf of the entire Board, I extend our gratitude to Sen for his many contributions to Terns during his CEO tenure.
  • We wish all the best for Sen and his family and will always consider him a member of the Terns team,” said David Fellows, Chairman of the Board of Terns.

ImmunoGen Announces Results from the Phase 3 MIRASOL Trial Selected as Late-Breaking Presentation for ASCO 2023 Annual Meeting

Retrieved on: 
Tuesday, May 9, 2023

"We are honored that MIRASOL has been selected as a late-breaker presentation at ASCO, and pleased that we will be able to share the results from the trial so quickly after they became available," said Anna Berkenblit, MD, Senior Vice President and Chief Medical Officer of ImmunoGen.

Key Points: 
  • "We are honored that MIRASOL has been selected as a late-breaker presentation at ASCO, and pleased that we will be able to share the results from the trial so quickly after they became available," said Anna Berkenblit, MD, Senior Vice President and Chief Medical Officer of ImmunoGen.
  • "Having demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to investigator's choice of single-agent chemotherapy, I believe ELAHERE has the potential to be practice changing in FRα-positive, platinum-resistant ovarian cancer."
  • Title: Phase III MIRASOL (GOG 3045/ENGOT-ov55) Study: Initial Report of Mirvetuximab Soravtansine vs.
  • ImmunoGen will present two additional trial-in-progress posters at ASCO.

National Kidney Foundation Innovation Fund Announces Investment in Relavo

Retrieved on: 
Wednesday, February 15, 2023

NEW YORK, Feb. 15, 2023 /PRNewswire/ -- The National Kidney Foundation (NKF) today announced the latest investment from its Innovation Fund, the philanthropic impact investment program of NKF. Relavo, a female-founded company dedicated to making home dialysis more accessible, will receive an investment to further develop its PeritoneX® technology to make peritoneal dialysis (PD) safer for patients.

Key Points: 
  • NEW YORK, Feb. 15, 2023 /PRNewswire/ -- The National Kidney Foundation (NKF) today announced the latest investment from its Innovation Fund , the philanthropic impact investment program of NKF.
  • Relavo , a female-founded company dedicated to making home dialysis more accessible, will receive an investment to further develop its PeritoneX® technology to make peritoneal dialysis (PD) safer for patients.
  • Launched in 2022, the NKF Innovation Fund works to accelerate funding, development, and commercialization of therapies that kidney patients need and deserve.
  • To learn more about kidney disease and how to maintain optimal kidney health, visit www.kidney.org/ .

Dr. Scott & Jill Kelley Introduce Life-Saving Medical Technology to Curb Postoperative Complications and Deaths

Retrieved on: 
Tuesday, December 20, 2022

TAMPA, FLORIDA, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Dr. Scott & Jill Kelley Introduce Life-Saving Medical Technology to Curb Postoperative Complications and Deaths

Key Points: 
  • TAMPA, FLORIDA, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Dr. Scott & Jill Kelley Introduce Life-Saving Medical Technology to Curb Postoperative Complications and Deaths
    Entrepreneurs Dr. Scott and Jill Kelley and Harvard University’s Biotechnology Club have brilliantly combined forces to develop an innovative surgical solution to protect millions of patients from leaks after surgery: A “medical-grade” biodegradable stent placed at the time of surgery that slowly dissolves over time.
  • This proprietary technology is a biodegradable device designed to provide a barrier to protect patients from leaks, improve quality of life, shorten post-operative recovery time, and curb healthcare costs.
  • They have proudly partnered with the Harvard Biotechnology Club to help bring this life-saving device to market.
  • LeakGuardTM will become a game-changer in the healthcare world by saving millions of lives and billions of dollars,” says Dr. Scott Kelley, CEO of SafeGuard Surgical.

Cantargia's CAN10 demonstrates positive activity in systemic sclerosis models in new data presented at ACR Convergence 2022

Retrieved on: 
Tuesday, November 8, 2022

LUND, Sweden, Nov. 8, 2022 /PRNewswire/ -- Cantargia (Cantargia AB) (Nasdaq Stockholm: CANTA) today reported new preclinical data demonstrating positive effects of the IL1RAP-binding antibody CAN10 in three different in vivo models of systemic sclerosis, a lead indication for the drug candidate. Across the models, which mimic difficult-to-treat forms of the disease, CAN10 reduced both pathological inflammation and fibrosis in skin and lung tissue, factors associated with clinical severity in humans. CAN10 also normalized a number of biomarkers closely associated with the human disease. The data have been selected for an oral presentation at ACR Convergence 2022, held in Philadelphia, November 10-14, 2022.

Key Points: 
  • The data have been selected for an oral presentation at ACR Convergence 2022, held in Philadelphia, November 10-14, 2022.
  • "We are pleased to build on previous exciting data on the effects of CAN10 in a number of models of life-threatening diseases.
  • The new results, selected for oral presentation at the prestigious ACR Convergence, demonstrate the potential of CAN10 in systemic sclerosis.
  • The new results show potent activity of a CAN10 surrogate antibody, which reduced inflammation and fibrosis in three different preclinical in vivo models of systemic sclerosis.

On World Polio Day 2022, PharmaJet Announces $1.5 million Grant From USAID to Evaluate Use of Needle-Free Delivery in Routine Polio Immunization

Retrieved on: 
Monday, October 24, 2022

The project will measure vaccine coverage and cost using Tropis ID for fractional inactivated poliovirus vaccine (IPV) delivery compared to standard intramuscular delivery using needle and syringe (N/S).

Key Points: 
  • The project will measure vaccine coverage and cost using Tropis ID for fractional inactivated poliovirus vaccine (IPV) delivery compared to standard intramuscular delivery using needle and syringe (N/S).
  • A preferred approach by healthcare workers and patients1 is needle-free ID delivery using Tropis, which was developed with support from the World Health Organization (WHO) and Bill & Melinda Gates Foundation.
  • On this World Polio Day 2022, we restate our commitment to the Global Polio Eradication Initiative and we are pleased to receive this grant from USAID Development Innovation Ventures.
  • Their advocacy efforts have played a role in decisions by governments to contribute more than $10 billion to the effort.